Clinical Trial Update: Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety and immune response of the dengue vaccine candidate rDEN3/4delta30[ME] in healthy adults. The study assesses tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• rDEN3/4delta30[ME] dengue vaccine (rDEN3/4delta30[ME] dengue vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED